Search Medical Condition
Please enter condition
Please choose location from dropdown

Belleville, New Jersey Clinical Trials

A listing of Belleville, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (655) clinical trials

Protocol: SHP643-301 An open-label, phase 3 research study of a subcutaneous investigational drug for children with Hereditary Angioedema who are 2 to < 12 years of age at the time of study enrollment. Note: all people who take part in the research study will receive the investigational drug. The study ...

Phase

0.0 miles

Learn More »

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

Phase

0.13 miles

Learn More »

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Phase

0.13 miles

Learn More »

Clinical Effectiveness Assessment of VeriStrat Testing and Validation of Immunotherapy Tests in NSCLC Subjects

The primary purpose of this observational study is to assess the physician's clinical practice patterns while using VeriStrat testing in subjects with NSCLC whose tumors are epidermal growth factor receptor (EGFR) wild-type (negative) or have unknown EGFR mutational status. This study will also attempt to further validate that VeriStrat test ...

Phase N/A

0.13 miles

Learn More »

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

The goal of asthma treatment is to achieve and maintain asthma control and to reduce the future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most effective anti- inflammatory treatment for all severities of persistent asthma. For children >=5 years of age and adolescents whose asthma is uncontrolled, ...

Phase

0.13 miles

Learn More »

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

PSOLAR is an 8 year registry study. A registry is an observational study that evaluates the status of a disease. This registry study will only include patients who volunteer to take part. About 4000 infliximab-exposed patients, 4000 ustekinumab-exposed patients and as well as a comparable number of patients (4000) on ...

Phase N/A

0.13 miles

Learn More »

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

BC-819 (inodiftagene vixteplasmid) is a recombinant DNA plasmid that directs the expression of a potent toxin specifically in malignant cells but not in normal tissue. It has been designed to exploit the established biology of the H19 gene, which is upregulated and expressed at high levels only in malignant cells, ...

Phase

0.69 miles

Learn More »

A Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the Renexus implants in participants with macular telangiectasia type 2.

Phase

1.37 miles

Learn More »

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

The ProVent Study is designed to look at subjects who recieve sipuleucel-T compared to control subjects followed on AS. The study will enroll subjects being followed by AS and initially diagnosed within 12 months prior to Screening with either ISUP Grade Group 1 or 2 adenocarcinoma of the prostate. The ...

Phase

1.37 miles

Learn More »

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 or Phase III Study ...

Phase

1.37 miles

Learn More »